Cargando…

Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1

BACKGROUND: Endometrial cancer (EC) is the 8(th) leading cause of cancer death amongst American women. Most ECs are endometrioid, serous, or clear cell carcinomas, or an admixture of histologies. Serous and clear ECs are clinically aggressive tumors for which alternative therapeutic approaches are n...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudd, Meghan L, Mohamed, Hassan, Price, Jessica C, O’Hara, Andrea J, Le Gallo, Matthieu, Urick, Mary Ellen, Cruz, Pedro, Zhang, Suiyuan, Hansen, Nancy F, Godwin, Andrew K, Sgroi, Dennis C, Wolfsberg, Tyra G, Mullikin, James C, Merino, Maria J, Bell, Daphne W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258955/
https://www.ncbi.nlm.nih.gov/pubmed/25427824
http://dx.doi.org/10.1186/1471-2407-14-884
_version_ 1782347940786864128
author Rudd, Meghan L
Mohamed, Hassan
Price, Jessica C
O’Hara, Andrea J
Le Gallo, Matthieu
Urick, Mary Ellen
Cruz, Pedro
Zhang, Suiyuan
Hansen, Nancy F
Godwin, Andrew K
Sgroi, Dennis C
Wolfsberg, Tyra G
Mullikin, James C
Merino, Maria J
Bell, Daphne W
author_facet Rudd, Meghan L
Mohamed, Hassan
Price, Jessica C
O’Hara, Andrea J
Le Gallo, Matthieu
Urick, Mary Ellen
Cruz, Pedro
Zhang, Suiyuan
Hansen, Nancy F
Godwin, Andrew K
Sgroi, Dennis C
Wolfsberg, Tyra G
Mullikin, James C
Merino, Maria J
Bell, Daphne W
author_sort Rudd, Meghan L
collection PubMed
description BACKGROUND: Endometrial cancer (EC) is the 8(th) leading cause of cancer death amongst American women. Most ECs are endometrioid, serous, or clear cell carcinomas, or an admixture of histologies. Serous and clear ECs are clinically aggressive tumors for which alternative therapeutic approaches are needed. The purpose of this study was to search for somatic mutations in the tyrosine kinome of serous and clear cell ECs, because mutated kinases can point to potential therapeutic targets. METHODS: In a mutation discovery screen, we PCR amplified and Sanger sequenced the exons encoding the catalytic domains of 86 tyrosine kinases from 24 serous, 11 clear cell, and 5 mixed histology ECs. For somatically mutated genes, we next sequenced the remaining coding exons from the 40 discovery screen tumors and sequenced all coding exons from another 72 ECs (10 clear cell, 21 serous, 41 endometrioid). We assessed the copy number of mutated kinases in this cohort of 112 tumors using quantitative real time PCR, and we used immunoblotting to measure expression of these kinases in endometrial cancer cell lines. RESULTS: Overall, we identified somatic mutations in TNK2 (tyrosine kinase non-receptor, 2) and DDR1 (discoidin domain receptor tyrosine kinase 1) in 5.3% (6 of 112) and 2.7% (3 of 112) of ECs. Copy number gains of TNK2 and DDR1 were identified in another 4.5% and 0.9% of 112 cases respectively. Immunoblotting confirmed TNK2 and DDR1 expression in endometrial cancer cell lines. Three of five missense mutations in TNK2 and one of two missense mutations in DDR1 are predicted to impact protein function by two or more in silico algorithms. The TNK2(P761Rfs*72) frameshift mutation was recurrent in EC, and the DDR1(R570Q) missense mutation was recurrent across tumor types. CONCLUSIONS: This is the first study to systematically search for mutations in the tyrosine kinome in clear cell endometrial tumors. Our findings indicate that high-frequency somatic mutations in the catalytic domains of the tyrosine kinome are rare in clear cell ECs. We uncovered ten new mutations in TNK2 and DDR1 within serous and endometrioid ECs, thus providing novel insights into the mutation spectrum of each gene in EC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2407-14-884) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4258955
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42589552014-12-09 Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1 Rudd, Meghan L Mohamed, Hassan Price, Jessica C O’Hara, Andrea J Le Gallo, Matthieu Urick, Mary Ellen Cruz, Pedro Zhang, Suiyuan Hansen, Nancy F Godwin, Andrew K Sgroi, Dennis C Wolfsberg, Tyra G Mullikin, James C Merino, Maria J Bell, Daphne W BMC Cancer Research Article BACKGROUND: Endometrial cancer (EC) is the 8(th) leading cause of cancer death amongst American women. Most ECs are endometrioid, serous, or clear cell carcinomas, or an admixture of histologies. Serous and clear ECs are clinically aggressive tumors for which alternative therapeutic approaches are needed. The purpose of this study was to search for somatic mutations in the tyrosine kinome of serous and clear cell ECs, because mutated kinases can point to potential therapeutic targets. METHODS: In a mutation discovery screen, we PCR amplified and Sanger sequenced the exons encoding the catalytic domains of 86 tyrosine kinases from 24 serous, 11 clear cell, and 5 mixed histology ECs. For somatically mutated genes, we next sequenced the remaining coding exons from the 40 discovery screen tumors and sequenced all coding exons from another 72 ECs (10 clear cell, 21 serous, 41 endometrioid). We assessed the copy number of mutated kinases in this cohort of 112 tumors using quantitative real time PCR, and we used immunoblotting to measure expression of these kinases in endometrial cancer cell lines. RESULTS: Overall, we identified somatic mutations in TNK2 (tyrosine kinase non-receptor, 2) and DDR1 (discoidin domain receptor tyrosine kinase 1) in 5.3% (6 of 112) and 2.7% (3 of 112) of ECs. Copy number gains of TNK2 and DDR1 were identified in another 4.5% and 0.9% of 112 cases respectively. Immunoblotting confirmed TNK2 and DDR1 expression in endometrial cancer cell lines. Three of five missense mutations in TNK2 and one of two missense mutations in DDR1 are predicted to impact protein function by two or more in silico algorithms. The TNK2(P761Rfs*72) frameshift mutation was recurrent in EC, and the DDR1(R570Q) missense mutation was recurrent across tumor types. CONCLUSIONS: This is the first study to systematically search for mutations in the tyrosine kinome in clear cell endometrial tumors. Our findings indicate that high-frequency somatic mutations in the catalytic domains of the tyrosine kinome are rare in clear cell ECs. We uncovered ten new mutations in TNK2 and DDR1 within serous and endometrioid ECs, thus providing novel insights into the mutation spectrum of each gene in EC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2407-14-884) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-26 /pmc/articles/PMC4258955/ /pubmed/25427824 http://dx.doi.org/10.1186/1471-2407-14-884 Text en © Rudd et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Rudd, Meghan L
Mohamed, Hassan
Price, Jessica C
O’Hara, Andrea J
Le Gallo, Matthieu
Urick, Mary Ellen
Cruz, Pedro
Zhang, Suiyuan
Hansen, Nancy F
Godwin, Andrew K
Sgroi, Dennis C
Wolfsberg, Tyra G
Mullikin, James C
Merino, Maria J
Bell, Daphne W
Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1
title Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1
title_full Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1
title_fullStr Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1
title_full_unstemmed Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1
title_short Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1
title_sort mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in tnk2 and ddr1
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258955/
https://www.ncbi.nlm.nih.gov/pubmed/25427824
http://dx.doi.org/10.1186/1471-2407-14-884
work_keys_str_mv AT ruddmeghanl mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT mohamedhassan mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT pricejessicac mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT oharaandreaj mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT legallomatthieu mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT urickmaryellen mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT cruzpedro mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT zhangsuiyuan mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT hansennancyf mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT godwinandrewk mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT sgroidennisc mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT wolfsbergtyrag mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT mullikinjamesc mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT merinomariaj mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1
AT belldaphnew mutationalanalysisofthetyrosinekinomeinserousandclearcellendometrialcanceruncoversraresomaticmutationsintnk2andddr1